One case of muscle loss induced by ceftazidime-avibactam for injection combined with polymyxins B sulfate for injection after renal transplantation

doi:10.19803/j.1672-8629.20220446

Abstract

Abstract: Objective To study the safety of ceftazidime-avibactam for injection combined with polymyxins B Sulfate for injection in patients after renal transplantation. Methods The clinical data of a 29-year-old female patient with Klebsiella pneumonia infection after renal transplantation was analyzed, who had been treated with intravenous infusion of polymyxin B sulfate for injection and ceftazidime-avibactam, but her kidney preservation solution was sensitive to colistin and ceftazidime-avibactam. She presented with weakness of muscle during infusion of the sixth dose of ceftazidime-avibactam for injection. The possible causes of adverse reactions were analyzed. Results Based on the Karch and Lasagna method and Naranjo scale, both polymyxin B sulfate and ceftazidime-avibactam were discontinued. These symptoms did not recur after the patient received intravenous infusion of ceftazidime-avibactam alone. Conclusion The combination of ceftazidime-avibactam for injection and polymyxin B sulfate for injection may increase the risk of weakness of muscle.

Key words: ceftazidime-avibactam, polymyxin B sulfate, injection, kidney transplantation, weakness of muscle, infection, safety, adverse drug reaction

CLC Number:

HUANG Shaolan, YANG Ge, LI Wei. One case of muscle loss induced by ceftazidime-avibactam for injection combined with polymyxins B sulfate for injection after renal transplantation[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 583-584.

References

[1] RASHID MU, ROSENBORG S, PANAGIOTIDIS G, et a1. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiot[J]. Int J Antimicrob Agents, 2015, 46(11): 60-65.
[2] WAGENLENHNER FM, SOBEL JD, NEWELL P, et al.Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections,including acute pyelonephritis: Recapture, a phase 3 randomized trial program[J]. ClinInfect Dis Radiol, 20l6, 63(15): 754-762.
[3] CARMELIY, ARMSTRONG J, LAUD PJ, et a1. Ceftazidime-avibactam or best availble therapy in patients with Ceftazidime-resistant enterobcteriaceae and pseudomonasaeruginosa complicated intra-abdominal infections(reprise):a randomised, pathogen-directed, phase 3 study[J]. Lancet Infect Dis, 2016, 16(6): 661-673.
[4] KUANG H, ZHONG C, WANG Y, et a1. Clinical characteristics and outcomes of patients with multidrug-resistant gram-negative bacterial infections treated with ceftazidime/avibactam[J]. J Glob Antimicrob Resist, 2020, 23: 404-407.
[5] ZHANG M, MA SL, YAN CC, et a1. Analysis of 99 cases of adverse reactions caused by ceftazidime in children[J].Chinese Journal of Rational Drug Use(中国合理用药探索), 2021, 18(5): 33-36.
[6] LIU XD, ZHANG PP, YU D, et a1. Literature analysis of adverse drug reactions induced by ceftazidime-avibactam[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2020, 36(16): 2504-2506.
[7] GATTI M, RASCHI E, PONTI FD.Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis[J]. Eur J Clin Microbiol Infect Dis, 2021, 40(6): 1169-1176.
[8] SOUSA A, PÉREZ-RODRÍGUEZ MT, SOTO A, et al. Effectiveness of ceftazidime-avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae[J]. J Antimicrob Chemother, 2018, 73(11): 3170-3175.
[9] LIU YL, SU NXU T.A case report of ceftazidime accumulation tremor in extremities caused by iodimeporeinduced renal injury[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2021, 30(8): 567-569.
[10] YE C, XIE JY, HU Y, et al.Therapeutic drug monitoring in a antibiotic encepha-lopathy patient induced by ceftazidime involved by clinical pharmacists[J]. Anti-Infection Pharmacy(抗感染药学), 2020, 17(5): 716-719.
[11] TIAN X, ZHANG HM, SUI LR, et al.A case of lip and gingival numbness caused by ceftazidime[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 38(23): 2499-2500.
[12] NATION RL, FORREST A.Clinical pharmacokinetics, pharmacodynamics and toxicodynamics of polymyxins: implications for therapeutic use[J]. Adv Exp Med Biol, 2019, 1145: 219-249.
[13] FALAGAS ME, KASIAKOU SK.Toxicity of polymyxins: a systematic review of the evidence from old and recent studies[J]. Crit Care, 2006, 10(1): R27.
[14] KARCH FE, LASAGNA L.Toward the operational identification of adverse drug reactions[J]. Clin Pharmacol Ther, 1977, 21: 247-25.
[15] NARANIO CA, BUSTO U, SELLERS EM, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[16] HERRERO FS.Ceftazidime-avibactam[J]. Rev Esp Quimioter, 2022, 35(1): 40-42.
[17] GUO XL, JIAN HC, ZHANG ZQ, et al.Signal mining and analysis of adverse drug reactions associated with nervous system disorders induced by ceftazidime/avibactam based on FAER database[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(19): 2046-2050.